LXRX

Lexicon Pharmaceuticals, Inc. NASDAQ Listed Apr 7, 2000

Healthcare ·Biotechnology ·US · lexpharma.com

$1.60

After hrs $1.64 +2.26%

Mkt Cap $677.9M

52w Low $0.51 75.7% of range 52w High $1.95

50d MA $1.66 200d MA $1.38

P/E (TTM) -11.6x

EV/EBITDA -9.2x

P/B 5.5x

Debt/Equity 0.6x

ROE -46.8%

P/FCF -6.2x

RSI (14) —

ATR (14) —

Beta 0.95

50d MA $1.66

200d MA $1.38

Avg Volume 2.7M

About

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 5, 2026	AMC	-0.07	-0.04	+42.9%	1.64	+0.0%	+4.3%	+2.4%	+1.2%	+4.9%	+4.9%	—
Nov 6, 2025	AMC	-0.07	-0.04	+42.9%	1.43	-2.8%	-12.6%	-0.7%	+9.1%	+7.7%	+0.7%	—
Aug 6, 2025	AMC	-0.08	0.01	+112.5%	1.15	+2.6%	-2.6%	-6.1%	-9.6%	-7.8%	-3.5%	—
May 13, 2025	AMC	-0.10	-0.07	+30.0%	0.63	-7.9%	-15.6%	-15.9%	-15.0%	-11.8%	-9.5%	—
Mar 6, 2025	AMC	-0.11	-0.09	+18.2%	0.37	+6.1%	+6.6%	-3.5%	-2.5%	+3.6%	-2.9%	—
Nov 12, 2024	AMC	-0.17	-0.18	-5.9%	1.19	-0.8%	-8.4%	-10.9%	-18.1%	-23.9%	-26.0%	—
Aug 1, 2024	AMC	-0.18	-0.17	+5.6%	2.02	-15.8%	-15.8%	-24.8%	-18.8%	-22.8%	-16.8%	—
May 2, 2024	AMC	-0.18	-0.20	-11.1%	1.70	-2.4%	+2.4%	+7.6%	+4.1%	+4.1%	+11.2%	—
Mar 11, 2024	AMC	-0.23	-0.20	+13.0%	2.81	+0.4%	-10.3%	-11.7%	-13.5%	-7.5%	-10.3%	—
Nov 8, 2023	AMC	-0.22	-0.21	+4.5%	1.14	-0.9%	-9.2%	-11.4%	-6.1%	-1.8%	+0.0%	—
Aug 3, 2023	AMC	-0.17	-0.22	-29.4%	1.92	-6.2%	-2.6%	-11.5%	-5.2%	-9.9%	-10.4%	—
May 2, 2023	AMC	-0.17	-0.17	+0.0%	2.38	+4.6%	+15.1%	+29.4%	+46.6%	+37.0%	+27.3%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.56	$1.56	+0.0%	+5.1%	+10.3%	+7.7%	+4.5%	+5.8%
Mar 10	Citigroup	Maintains	Buy → Buy	—	$1.68	$1.72	+2.4%	-1.2%	+2.4%	+2.4%	+0.6%	-4.2%
Mar 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.63	$1.54	-5.5%	+0.6%	+4.9%	+3.1%	+1.8%	+5.5%
Sep 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.10	$1.12	+1.8%	+1.8%	-1.8%	-2.7%	-0.9%	-1.8%
Aug 7	Citigroup	Maintains	Buy → Buy	—	$1.15	$1.18	+2.6%	-2.6%	-6.1%	-9.6%	-7.8%	-3.5%
Jun 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.73	$0.75	+1.9%	+4.9%	+22.4%	+26.6%	+11.8%	+28.8%
Mar 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.35	$0.65	+88.4%	+64.1%	+32.6%	+33.5%	+44.7%	+27.5%
Mar 7	Piper Sandler	Maintains	Overweight → Overweight	—	$0.37	$0.39	+6.1%	+6.6%	-3.5%	-2.5%	+3.6%	-2.9%
Mar 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.37	$0.39	+6.1%	+6.6%	-3.5%	-2.5%	+3.6%	-2.9%
Mar 7	Needham	Maintains	Hold → Hold	—	$0.37	$0.39	+6.1%	+6.6%	-3.5%	-2.5%	+3.6%	-2.9%
Mar 4	Leerink Partners	Downgrade	Outperform → Market Perform	—	$0.29	$0.31	+4.6%	+11.0%	+14.8%	+25.7%	+33.9%	+21.2%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.70	$0.37	-46.4%	-58.2%	-53.6%	-52.0%	-47.4%	-44.0%
Mar 3	Needham	Maintains	Hold → Hold	—	$0.70	$0.37	-46.4%	-58.2%	-53.6%	-52.0%	-47.4%	-44.0%
Jan 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.93	$0.94	+0.7%	-11.3%	-11.9%	-18.7%	-21.8%	-18.3%
Jan 29	Needham	Maintains	Hold → Hold	—	$0.93	$0.94	+0.7%	-11.3%	-11.9%	-18.7%	-21.8%	-18.3%
Dec 23	Needham	Maintains	Hold → Hold	—	$0.71	$0.67	-5.8%	+15.7%	+6.0%	+9.8%	+8.2%	+0.7%
Nov 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.19	$1.18	-0.8%	-8.4%	-10.9%	-18.1%	-23.9%	-26.0%
Nov 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.21	$1.20	-0.8%	-1.7%	+0.0%	+7.4%	+5.0%	+5.0%
Nov 1	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.95	$1.20	-38.5%	-37.4%	-37.9%	-39.0%	-37.9%	-33.3%
Oct 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.03	$2.01	-1.0%	-3.9%	-3.9%	-39.9%	-40.4%	-41.4%
Oct 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.94	$1.96	+1.0%	-4.1%	-5.2%	-7.2%	-4.1%	+4.6%
Oct 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.91	$1.93	+1.0%	+5.2%	+8.9%	+2.1%	+1.6%	-2.6%
Oct 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.61	$1.60	-0.6%	+0.0%	+5.0%	+4.3%	+4.3%	+1.2%
Sep 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.54	$1.56	+1.3%	+3.9%	+1.9%	+2.6%	+4.5%	+4.5%
Sep 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.67	$1.68	+0.6%	+1.2%	+0.0%	+1.8%	-2.4%	-3.0%
Sep 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.73	$1.72	-0.6%	-6.9%	-5.8%	-6.4%	-6.9%	-3.5%
Aug 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.68	$1.69	+0.6%	+13.7%	+8.9%	+8.9%	+5.4%	+2.4%
Aug 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.59	$1.60	+0.6%	+8.8%	+3.1%	+3.1%	+4.4%	+6.3%
Aug 2	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.02	$1.70	-15.8%	-15.8%	-24.8%	-18.8%	-22.8%	-16.8%
Jul 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.12	$2.13	+0.5%	+5.2%	+0.5%	-1.4%	-6.1%	-0.5%
Jun 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.85	$1.85	+0.0%	-2.2%	-8.1%	-9.2%	-5.9%	-9.2%
May 31	Citigroup	Maintains	Buy → Buy	—	$2.90	$2.91	+0.3%	+13.8%	-6.6%	-5.2%	-12.4%	-8.3%
May 30	Needham	Maintains	Hold → Hold	—	$3.18	$3.40	+6.9%	-8.8%	+3.8%	-14.8%	-13.5%	-20.1%
Mar 7	Jefferies	Maintains	Hold → Hold	—	$2.60	$2.57	-1.2%	-0.8%	-6.2%	-13.1%	-15.0%	-11.2%
Nov 22	Citigroup	Maintains	Buy → Buy	—	$2.19	$2.22	+1.4%	+1.4%	-2.7%	-2.7%	-7.8%	-6.4%
Aug 12	Piper Sandler	Maintains	Overweight → Overweight	—	$2.76	$2.90	+5.1%	+14.9%	+24.3%	+18.8%	+10.9%	+12.3%
Jul 1	Citigroup	Maintains	Buy → Buy	—	$1.86	$1.92	+3.2%	+4.3%	+47.8%	+41.4%	+51.1%	+54.3%
Jan 29	Wedbush	Downgrade	Outperform → Neutral	—	$8.06	$8.02	-0.5%	-1.9%	+2.6%	+12.8%	+6.9%	+5.3%
Jan 29	JP Morgan	Upgrade	Underweight → Neutral	—	$8.06	$8.02	-0.5%	-1.9%	+2.6%	+12.8%	+6.9%	+5.3%
Dec 8	Citigroup	Upgrade	Neutral → Buy	—	$1.73	$2.35	+35.8%	+78.0%	+67.6%	+91.9%	+80.3%	+72.3%
Nov 18	Gabelli & Co.	Upgrade	Hold → Buy	—	$1.81	$1.81	+0.0%	-11.6%	-14.4%	-17.1%	-19.3%	-12.7%
Apr 28	Citigroup	Maintains	Neutral → Neutral	—	$2.30	$2.33	+1.3%	-7.8%	-7.8%	-17.8%	-17.4%	-17.8%
Dec 11	Gabelli & Co.	Downgrade	Buy → Hold	—	$5.15	$5.01	-2.7%	-1.9%	-1.6%	-5.6%	-5.8%	-10.7%
Nov 8	Citigroup	Downgrade	Buy → Neutral	—	$3.88	$3.76	-3.1%	-9.3%	-8.5%	-9.5%	-10.6%	-11.9%
Sep 11	Gabelli & Co.	Upgrade	Hold → Buy	—	$1.72	$2.36	+37.2%	+27.9%	+40.7%	+36.0%	+59.3%	+70.9%
Jul 30	Citigroup	Maintains	Buy → Buy	—	$1.69	$1.70	+0.6%	-1.8%	-20.1%	-22.5%	-29.0%	-21.3%
Jul 29	Stifel Nicolaus	Downgrade	Buy → Hold	—	$5.69	$2.47	-56.6%	-70.3%	-70.8%	-76.3%	-77.0%	-78.9%
Jul 29	Stifel	Downgrade	Buy → Hold	—	$5.69	$2.47	-56.6%	-70.3%	-70.8%	-76.3%	-77.0%	-78.9%
Mar 25	Gabelli & Co.	Upgrade	Sell → Hold	—	$6.20	$5.95	-4.0%	-8.7%	-12.7%	-14.2%	-15.2%	-10.3%
Mar 14	Gabelli & Co.	Downgrade	Hold → Sell	—	$7.86	$7.34	-6.6%	-6.7%	-5.7%	-3.1%	-0.8%	-1.5%

Recent Filings

8-K

Lexicon Pharmaceuticals, Inc. -- 8-K Filing

Lexicon Pharmaceuticals received FDA clearance for pilavapadin Phase 3 development and secured over $100 million in cash from a capital raise and Novo Nordisk milestone payment, strengthening its financial position.

Mar 5

8-K · 1.01 ! Medium

Lexicon Pharmaceuticals, Inc. -- 8-K 1.01: Equity Issuance

Lexicon Pharmaceuticals raised $41.6 million through a public equity offering underwritten by Jefferies LLC, providing capital for drug development and operations.

Feb 2

Data updated apr 25, 2026 8:14pm · Source: massive.com